Woodline Partners LP Acquires 814,917 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Woodline Partners LP significantly increased its stake in Edwards Lifesciences Corporation by 7,805.0%, acquiring a total of 825,358 shares valued at approximately $59.8 million.
• Multiple institutional investors, including Quantbot Technologies LP and Global X Japan Co. Ltd., also established or expanded their positions in Edwards Lifesciences during recent quarters, leading to a total of 79.46% institutional ownership.
• Edwards Lifesciences reported strong quarterly results with earnings per share of $0.67, surpassing estimates, and analysts have set a consensus price target of $85.90 for the stock.

Woodline Partners LP raised its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 7,805.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 825,358 shares of the medical research company's stock after purchasing an additional 814,917 shares during the period. Woodline Partners LP owned 0.14% of Edwards Lifesciences worth $59,822,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. MBB Public Markets I LLC bought a new stake in Edwards Lifesciences in the first quarter valued at $313,000. Vancity Investment Management Ltd bought a new stake in Edwards Lifesciences in the first quarter valued at $9,367,000. Caxton Associates LLP bought a new stake in Edwards Lifesciences in the first quarter valued at $370,000. Sciencast Management LP bought a new stake in Edwards Lifesciences in the first quarter valued at $208,000. Finally, Voleon Capital Management LP bought a new stake in Edwards Lifesciences in the first quarter valued at $1,066,000. 79.46% of the stock is owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,014 shares of company stock worth $1,698,844. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Down 0.7%

Edwards Lifesciences stock traded down $0.51 during midday trading on Friday, hitting $77.50. 6,301,589 shares of the stock were exchanged, compared to its average volume of 3,595,766. Edwards Lifesciences Corporation has a 52-week low of $64.00 and a 52-week high of $83.00. The stock has a market capitalization of $45.50 billion, a price-to-earnings ratio of 11.15, a price-to-earnings-growth ratio of 3.76 and a beta of 1.07. The business's 50-day moving average price is $78.92 and its 200-day moving average price is $75.42. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same period in the previous year, the company earned $0.70 earnings per share. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the subject of several research analyst reports. Evercore ISI lifted their price target on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research note on Friday, July 25th. Truist Financial boosted their target price on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. Stifel Nicolaus boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. William Blair raised shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Finally, Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $86.26.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.